New Drug: Mirvetuximab Soravtansine in Advanced Ovarian Cancer

  • Study

    A Phase III, Randomized, Open-label trial (MIRASOL)
    Platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression
    Mirvetuximab soravtansine (n=227) vs SOC (n=226


  • Efficacy

    mPFS: 5.91 vs. 4.34 mos, HR:0.72, p=0.0082
    mOS: 16.46 vs. 12.75 mos, HR: 0.67, p=0.0046
    ORR: 36.1% vs.14.6%, p<0.0001

  • Safety

    Grade3: Keratophaty (9%vs.0), blurred vision (8% vs.0), neutropenia (1% vs.31%), thrombocytopenia (1% vs.27%).


    • Journal of Clin Oncol 2023 41:17_suppl, LBA5507-LBA5507

    Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator’s choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression.

    http://doi.org/10.1200/JCO.2023.41.17_suppl.LBA5507

    Reviewed by Elvin Chalabiyev, MD on Jun 24, 2023

    Altai Oncology App
    Download Altai Oncology App On App Store
    Download Altai Oncology App On Play Store
    • Chemotherapy Protocols
    • Summarized References
    • Oncology Drug Specs
    • TNM Staging
    • BSA, CrCl Calculator
    Back to top Drag